153 related articles for article (PubMed ID: 23176212)
1. Class- and molecule-specific differential effects of angiotensin II type 1 receptor blockers.
Imaizumi S; Miura S; Yahiro E; Uehara Y; Komuro I; Saku K
Curr Pharm Des; 2013; 19(17):3002-8. PubMed ID: 23176212
[TBL] [Abstract][Full Text] [Related]
2. Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects.
Miura S; Karnik SS; Saku K
J Renin Angiotensin Aldosterone Syst; 2011 Mar; 12(1):1-7. PubMed ID: 20603272
[TBL] [Abstract][Full Text] [Related]
3. Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.
Takezako T; Unal H; Karnik SS; Node K
Pharmacol Res; 2017 Sep; 123():40-50. PubMed ID: 28648738
[TBL] [Abstract][Full Text] [Related]
4. The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.
Wang X; Ye Y; Gong H; Wu J; Yuan J; Wang S; Yin P; Ding Z; Kang L; Jiang Q; Zhang W; Li Y; Ge J; Zou Y
J Mol Cell Cardiol; 2016 Aug; 97():180-90. PubMed ID: 27210827
[TBL] [Abstract][Full Text] [Related]
5. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
Michel MC; Foster C; Brunner HR; Liu L
Pharmacol Rev; 2013 Apr; 65(2):809-48. PubMed ID: 23487168
[TBL] [Abstract][Full Text] [Related]
6. Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter.
Iwanaga T; Sato M; Maeda T; Ogihara T; Tamai I
J Pharmacol Exp Ther; 2007 Jan; 320(1):211-7. PubMed ID: 17043154
[TBL] [Abstract][Full Text] [Related]
7. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b.
Marshall TG; Lee RE; Marshall FE
Theor Biol Med Model; 2006 Jan; 3():1. PubMed ID: 16403216
[TBL] [Abstract][Full Text] [Related]
8. A small difference in the molecular structure of angiotensin II receptor blockers induces AT₁ receptor-dependent and -independent beneficial effects.
Fujino M; Miura S; Kiya Y; Tominaga Y; Matsuo Y; Karnik SS; Saku K
Hypertens Res; 2010 Oct; 33(10):1044-52. PubMed ID: 20668453
[TBL] [Abstract][Full Text] [Related]
9. Reassessment of the unique mode of binding between angiotensin II type 1 receptor and their blockers.
Miura S; Nakao N; Hanzawa H; Matsuo Y; Saku K; Karnik SS
PLoS One; 2013; 8(11):e79914. PubMed ID: 24260317
[TBL] [Abstract][Full Text] [Related]
10. Structure-Function Basis of Attenuated Inverse Agonism of Angiotensin II Type 1 Receptor Blockers for Active-State Angiotensin II Type 1 Receptor.
Takezako T; Unal H; Karnik SS; Node K
Mol Pharmacol; 2015 Sep; 88(3):488-501. PubMed ID: 26121982
[TBL] [Abstract][Full Text] [Related]
11. Do all angiotensin II type 1 receptor blockers have the same beneficial effects?
Miura S; Saku K
Br J Pharmacol; 2007 Aug; 151(7):912-3. PubMed ID: 17572701
[TBL] [Abstract][Full Text] [Related]
12. Valsartan ameliorates the constitutive adipokine expression pattern in mature adipocytes: a role for inverse agonism of the angiotensin II type 1 receptor in obesity.
Hasan AU; Ohmori K; Hashimoto T; Kamitori K; Yamaguchi F; Ishihara Y; Ishihara N; Noma T; Tokuda M; Kohno M
Hypertens Res; 2014 Jul; 37(7):621-8. PubMed ID: 24599011
[TBL] [Abstract][Full Text] [Related]
13. Telmisartan has the strongest binding affinity to angiotensin II type 1 receptor: comparison with other angiotensin II type 1 receptor blockers.
Kakuta H; Sudoh K; Sasamata M; Yamagishi S
Int J Clin Pharmacol Res; 2005; 25(1):41-6. PubMed ID: 15864875
[TBL] [Abstract][Full Text] [Related]
14. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
[TBL] [Abstract][Full Text] [Related]
15. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans.
Coltamai L; Maillard M; Simon A; Vogt B; Burnier M
J Hypertens; 2010 Mar; 28(3):520-6. PubMed ID: 20104189
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective effects of AT1 receptor antagonists after experimental ischemic stroke: what is important?
Culman J; Jacob T; Schuster SO; Brolund-Spaether K; Brolund L; Cascorbi I; Zhao Y; Gohlke P
Naunyn Schmiedebergs Arch Pharmacol; 2017 Sep; 390(9):949-959. PubMed ID: 28669009
[TBL] [Abstract][Full Text] [Related]
17. Involvement of uric acid transporters in alteration of serum uric acid level by angiotensin II receptor blockers.
Sato M; Iwanaga T; Mamada H; Ogihara T; Yabuuchi H; Maeda T; Tamai I
Pharm Res; 2008 Mar; 25(3):639-46. PubMed ID: 17674156
[TBL] [Abstract][Full Text] [Related]
18. Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells.
Cianchetti S; Del Fiorentino A; Colognato R; Di Stefano R; Franzoni F; Pedrinelli R
Atherosclerosis; 2008 May; 198(1):22-8. PubMed ID: 17950296
[TBL] [Abstract][Full Text] [Related]
19. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor.
Le MT; Pugsley MK; Vauquelin G; Van Liefde I
Br J Pharmacol; 2007 Aug; 151(7):952-62. PubMed ID: 17572702
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
